A prospective study used droplet digital PCR to search for treatment-informative EGFR and KRAS mutations in cell-free DNA from non-small cell lung cancer patients.
In Nature this week: transcriptomic and epigenomic analysis of bat wing development, and more.
The group combined molecular barcoding and an error suppression computational method to enable the detection of mutations at a .004 percent frequency.
The Menlo Park, California-based firm plans to launch its test, which uses rolling circle amplification, this summer in China.
In PNAS this week: methylation patterns trace cell-free DNA to tissue of origin, cell surface proteome of Ewing sarcoma tumor cells, and more.
The team said their approach may have several applications, including evaluation of cellular response to therapies, and early diagnosis of diseases like cancer.
Researchers have designed new strategies to distinguish true variants from errors when trying to call very low frequency mutations in circulating tumor DNA.
Despite the gains it recorded for revenues in the quarter and the full year, the firm missed analyst estimates for both revenues and net loss for Q4 and 2015.
The firm found that for sub-chromosomal copy number variants, the test had a sensitivity of 97.7 percent and a specificity of 99.9 percent.
The company, based in Constance, Germany, is launching three liquid biopsy assays as a research service this week that differ in target size and sensitivity.
The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.
The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.
New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.
In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.